يعرض 1 - 10 نتائج من 16 نتيجة بحث عن '"N. CRESTI"', وقت الاستعلام: 0.86s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

    المؤلفون: R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, M. J. Seckl

    المصدر: Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)

    مصطلحات موضوعية: Science

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/2041-1723Test

    الوصول الحر: https://doaj.org/article/dd21946084ab4cad9d70fb08c6b96016Test

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

    المؤلفون: R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. Ferguson, M. J. Seckl

    المصدر: Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)

    مصطلحات موضوعية: Science

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/2041-1723Test

    الوصول الحر: https://doaj.org/article/a49b3f62276b4ad18eb4fc87fff91c8dTest

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  3. 3
    232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

    المؤلفون: D. Hanna, S. Merrick, A. Ghose, D. Yang, E. Phillips, N.R. Chopra, K. Ross, Z.Y. Boh, A. Swampillai, T. Robinson, L. Germain, C. Atkinson, A.A. Konstantis, P. Riddle, N. Cresti, J.D. Naik, A. Borley, A. Guppy, P. Schmid, M. Phillips

    المصدر: ESMO Open. 8:101420

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::59e2550f147fd9dfc131d1174dbe57f8Test
    https://doi.org/10.1016/j.esmoop.2023.101420Test


    أضف إلى المفضلة
  4. 4
    North East Experience on Pertuzumab, Trastuzumab and Docetaxel in Metastatic Breast Cancer

    المؤلفون: J. Veeratterapillay, N. Cresti, D. Lee, M. Verrill, R. Todd, L. Mariappan

    المصدر: Clinical Oncology. 32:e171-e172

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, North east, medicine.disease, Metastatic breast cancer, Docetaxel, Trastuzumab, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Pertuzumab, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f4594fe6f6d557ded61bd6f7f6bea8c3Test
    https://doi.org/10.1016/j.clon.2020.02.021Test


    أضف إلى المفضلة
  5. 5
    Abstract P4-21-08: A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer

    المؤلفون: Iain R. Macpherson, N Cresti, Y Takeda, S Kumar, J. Bonneterre, J Posner, A Arimura, Antoine Italiano, S Rafii, James Spicer, P Spiliopoulou, M Saggese, M. Campone, Richard D. Baird

    المصدر: Cancer Research. 77:P4-21

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Lapatinib, Vinorelbine, medicine.disease, Metastatic breast cancer, Gastroenterology, 03 medical and health sciences, 030104 developmental biology, Breast cancer, Tolerability, Trastuzumab, Internal medicine, medicine, Pertuzumab, skin and connective tissue diseases, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4d1b2f53f2746b1fc9aeb95345c73769Test
    https://doi.org/10.1158/1538-7445.sabcs16-p4-21-08Test


    أضف إلى المفضلة
  6. 6
    A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

    المؤلفون: N Cresti, Karen E Swales, Mark Merriman, Rodger A. Allen, Paul Bevan, Carola Mala, Richard H. Wilson, Alan V. Boddy, Malcolm R Ranson, T. R. Jeffery Evans, Alastair Greystoke, Vicky M. Coyle, Ruth Plummer, Yvette Drew, Julieann Sludden, Alan Anthoney, Lisa Jane Rodgers, MJ Griffin, David Jamieson, Udai Banerji, Emma Dean, Markus Buerkle

    المساهمون: Jamieson, David, Griffin, Melanie J, Sludden, Julieann, Drew, Yvette, Boddy, Alan V, Plummer, Ruth

    المصدر: Jamieson, D, Griffin, M, Sludden, J, Drew, Y, Cresti, N, Swales, K, Merriman, M, Allen, R, Bevan, P, Buerkle, M, Mala, C, Coyle, V, Rodgers, L, Dean, E, Greystoke, A, Banerji, U, Wilson, R, Evans, J, Anthoney, A, Ranson, M, Boddy, A & Plummer, R 2016, ' A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours ', European Journal of Cancer, vol. 68 . https://doi.org/10.1016/j.ejca.2016.08.026Test
    Jamieson, D, Griffin, M J, Sludden, J, Drew, Y, Cresti, N, Swales, K, Merriman, M, Allen, R, Bevan, P, Buerkle, M, Mala, C, Coyle, V, Rodgers, L, Dean, E, Greystoke, A, Banerji, U, Wilson, R H, Evans, T R J, Anthoney, A, Ranson, M, Boddy, A V & Plummer, R 2016, ' A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours ', European Journal of Cancer, vol. 68, pp. 1-10 . https://doi.org/10.1016/j.ejca.2016.08.026Test

    مصطلحات موضوعية: Male, Mesothelioma, 0301 basic medicine, Cancer Research, Lung Neoplasms, Esophageal Neoplasms, MAP Kinase Kinase 2, MAP Kinase Kinase 1, Administration, Oral, Uterine Cervical Neoplasms, Mitogen-activated protein kinase kinase, Pharmacology, Cholangiocarcinoma, 0302 clinical medicine, Tandem Mass Spectrometry, Carcinoma, Non-Small-Cell Lung, Neoplasms, Medicine, Chromatography, High Pressure Liquid, Fatigue, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Manchester Cancer Research Centre, Kinase, MEK inhibitor, Ribosomal Protein S6 Kinases, 70-kDa, Nausea, Middle Aged, Anorexia, Oncology, 030220 oncology & carcinogenesis, Toxicity, Female, Drug Eruptions, Colorectal Neoplasms, pharmacokinetics, Adult, Diarrhea, Maximum Tolerated Dose, Phase 1, optimal biological dose, 03 medical and health sciences, Phase I, Allosteric Regulation, SDG 3 - Good Health and Well-being, Pharmacokinetics, MEK Inhibitor WX-554, pharmacodynamics, Humans, Protein Kinase Inhibitors, Aged, Glycogen Synthase Kinase 3 beta, Performance status, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Phosphoproteins, Abdominal Pain, Pancreatic Neoplasms, 030104 developmental biology, Bile Duct Neoplasms, Pharmacodynamics, business, Proto-Oncogene Proteins c-akt, Chromatography, Liquid

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cfeb7e3462ba1cdff56aeaf39e4fa01Test
    https://doi.org/10.1016/j.ejca.2016.08.026Test


    أضف إلى المفضلة
  7. 7
    Abstract 1406: Are circulating microRNAs (miRNAs) ready for inclusion as biomarkers in breast cancer clinical trials

    المؤلفون: Rosie McNeillis, Michelle Harvie, N Cresti, Henry Cain, Felicity E. B. May, Jonathan Womack, Edward B. Amankwatia, David Jamieson, Sacha J Howell, Alastair Greystoke, Alexandra Bennett, David Ou

    المصدر: Cancer Research. 80:1406-1406

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Clinical trial, Circulating MicroRNA, Breast cancer, Statistical significance, Internal medicine, Cohort, medicine, Biomarker (medicine), business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::bcf5b93f63f7ea8eb9faa079da36c8c9Test
    https://doi.org/10.1158/1538-7445.am2020-1406Test


    أضف إلى المفضلة
  8. 8
    Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

    المؤلفون: Linda Hogarth, Debashis Sarker, Antoine Italiano, J Posner, N Cresti, Duncan I. Jodrell, K Donaldson, K Kawaguchi, S Deva, J. Garcia-Corbacho, Richard D. Baird, Ruth Plummer, A Arimura, Eugene P. Frenkel, James Spicer, H.-T. Arkenau

    المصدر: Cancer Research. 76:P4-14

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Pathology, medicine.drug_class, Population, Lapatinib, Tyrosine-kinase inhibitor, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, skin and connective tissue diseases, Adverse effect, education, education.field_of_study, business.industry, Cancer, medicine.disease, Metastatic breast cancer, 030104 developmental biology, 030220 oncology & carcinogenesis, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::a6642105895351cf70326a4d51c49ce2Test
    https://doi.org/10.1158/1538-7445.sabcs15-p4-14-26Test


    أضف إلى المفضلة
  9. 9
    Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

    المؤلفون: Ruth Plummer, Aneta Suder, N Cresti, J. Garcia Corbacho, I Kawabata, Duncan I. Jodrell, Linda Hogarth, James Spicer, S. Matsumoto, Eugene P. Frenkel, K Donaldson, J Posner, Debashis Sarker, Richard D. Baird

    المساهمون: Baird, Richard [0000-0001-7071-6483], Jodrell, Duncan [0000-0001-9360-1670], Apollo - University of Cambridge Repository

    المصدر: European Journal of Cancer. 51:137-145

    مصطلحات موضوعية: Adult, Diarrhea, Male, Oncology, Cancer Research, medicine.medical_specialty, Metabolic Clearance Rate, Receptor, ErbB-2, Nausea, medicine.drug_class, EGFR, Administration, Oral, Phases of clinical research, Pharmacology, Lapatinib, Drug Administration Schedule, Tyrosine-kinase inhibitor, Young Adult, Pharmacokinetics, Trastuzumab, HER2, Neoplasms, Internal medicine, medicine, Humans, HER4, Protein Kinase Inhibitors, Fatigue, Aged, Dose-Response Relationship, Drug, business.industry, Standard treatment, Phase 1 clinical trial, Exanthema, Middle Aged, Rash, ErbB Receptors, Treatment Outcome, Area Under Curve, Protein kinase inhibitor, Quinazolines, Female, medicine.symptom, business, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01df921a308d76dcf85bee3344db99deTest
    https://doi.org/10.1016/j.ejca.2014.11.003Test


    أضف إلى المفضلة
  10. 10
    Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

    المؤلفون: F Gao, J. Garcia Corbacho, Richard D. Baird, Ruth Plummer, Emma Beddowes, H.-T. Arkenau, Duncan I. Jodrell, C. Lemech, I Kawabata, M Saggese, Martin Forster, K Donaldson, J Posner, N Cresti, M Flynn, James Spicer

    المصدر: Cancer Research. 73:P4-12

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, medicine.drug_class, Cancer, Pharmacology, Lapatinib, medicine.disease, Rash, Metastatic breast cancer, Gastroenterology, Tyrosine-kinase inhibitor, Oncology, Pharmacokinetics, Trastuzumab, Pharmacodynamics, Internal medicine, Medicine, medicine.symptom, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8513e17ded6fd058f8e9f4e1524ffd7bTest
    https://doi.org/10.1158/0008-5472.sabcs13-p4-12-24Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث